X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (14) 14
male (12) 12
female (11) 11
index medicus (11) 11
adult (7) 7
aged (6) 6
analysis (6) 6
middle aged (6) 6
treatment outcome (6) 6
aged, 80 and over (4) 4
hematology (4) 4
chemotherapy (3) 3
drug therapy (3) 3
follow-up studies (3) 3
further section (3) 3
lymphomas (3) 3
neurosciences (3) 3
pediatrics (3) 3
prognosis (3) 3
risk factors (3) 3
adolescent (2) 2
antineoplastic combined chemotherapy protocols - adverse effects (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
azacitidine (2) 2
care and treatment (2) 2
central nervous system (2) 2
central nervous system neoplasms - drug therapy (2) 2
central nervous system neoplasms - mortality (2) 2
children (2) 2
chronic myelomonocytic leukemia (2) 2
clinical neurology (2) 2
cognitive impairment (2) 2
combined modality therapy (2) 2
critical illness (2) 2
elderly-patients (2) 2
health risks (2) 2
healthy ageing (2) 2
heart failure (2) 2
hematologic toxicity (2) 2
hemic and lymphatic diseases (2) 2
history and criticism (2) 2
infant (2) 2
italy (2) 2
lymphoma (2) 2
lymphoma, large b-cell, diffuse - drug therapy (2) 2
medicine & public health (2) 2
mortality (2) 2
myelodysplastic syndromes (2) 2
neoplasm recurrence, local - drug therapy (2) 2
non-hodgkin-lymphoma (2) 2
patient outcomes (2) 2
patients (2) 2
polymerase chain reaction (2) 2
retrospective studies (2) 2
risk-factors (2) 2
rituximab (2) 2
survival rate (2) 2
transplantation (2) 2
vascular diseases (2) 2
vitamins (2) 2
young adult (2) 2
1506 (1) 1
1840-1922 (1) 1
1922 (1) 1
1922-1998 (1) 1
1st report (1) 1
abridged index medicus (1) 1
access (1) 1
ace (1) 1
ace inhibitors (1) 1
acute disease (1) 1
acute lymphoblastic-leukemia (1) 1
aging - blood (1) 1
aging - pathology (1) 1
alzheimer disease (1) 1
alzheimer's disease (1) 1
america (1) 1
anesthesiology (1) 1
angina pectoris (1) 1
angiotensin (1) 1
angiotensin-converting enzyme inhibitors - therapeutic use (1) 1
animals (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
antineoplastic agents - adverse effects (1) 1
antioxidant status (1) 1
arabinonucleosides - adverse effects (1) 1
article (1) 1
artificial respiration (1) 1
ascorbic acid - blood (1) 1
ascorbic-acid (1) 1
atherosclerosis (1) 1
autografts (1) 1
autologous stem cell transplant (1) 1
b-cell lymphoma (1) 1
biographies (1) 1
biomarkers (1) 1
biomechanical phenomena - physiology (1) 1
blood circulation disorders (1) 1
blood-brain barrier - diagnostic imaging (1) 1
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
BMC Infectious Diseases, ISSN 1471-2334, 03/2017, Volume 17, Issue 1, p. 216
Background: Imported cases of infections due to Dengue (DENV) and Chikungunya (CHIKV) viruses and, more recently, Zika virus (ZIKV) are commonly reported among... 
DENGUE | INFECTIOUS DISEASES | AMERICA | NUMBER | STATES | 1ST REPORT | CHIKUNGUNYA VIRUS | OUTBREAK | ZIKA VIRUS-INFECTION | KOREICUS | VECTOR | Chikungunya Fever - diagnosis | Molecular Diagnostic Techniques - methods | Public Health | Zika Virus - genetics | Chikungunya virus - genetics | Humans | Male | Young Adult | Female | Chikungunya Fever - genetics | Chikungunya virus - isolation & purification | Zika Virus Infection - prevention & control | Dengue - genetics | Dengue - epidemiology | Genotype | Zika Virus - isolation & purification | Chikungunya Fever - transmission | Dengue Virus - genetics | Travel | Zika Virus Infection - transmission | Zika Virus Infection - diagnosis | Zika Virus Infection - epidemiology | Chikungunya Fever - epidemiology | Dengue - transmission | Disease Outbreaks - prevention & control | Italy - epidemiology | Dengue Virus - isolation & purification | Population Surveillance | Dengue - diagnosis | Immunoglobulin M | Vector-borne diseases | Epidemics | Laboratories | Dengue | Dengue fever | Health risks | Viral diseases | Viruses | Regional planning | Zika virus | Vectors | Polymerase chain reaction | Infectious diseases | Disease transmission | Surveillance | Sampling methods | Differential diagnosis | Diagnostic systems | Diagnosis | Genotypes | Enzyme-linked immunosorbent assay
Journal Article
Toxicology Letters, ISSN 0378-4274, 10/2017, Volume 280, pp. S318 - S318
Journal Article
Intensive Care Medicine, ISSN 0342-4642, 1/2011, Volume 37, Issue 1, pp. 124 - 131
Journal Article
BLOOD, ISSN 0006-4971, 07/2019, Volume 134, Issue 3, pp. 252 - 262
Patients with primary central nervous system lymphoma (PCNSL) are treated with high-dose methotrexate-based chemotherapy, which requires hospitalization and... 
SYSTEM | THERAPY | VESSELS | TARGETING AGENT | CYCLOPHOSPHAMIDE | VASCULATURE | NGR-HTNF | DOXORUBICIN | HEMATOLOGY | CANCER | TNF | Immunohistochemistry | Doxorubicin - therapeutic use | Humans | Tomography, Emission-Computed, Single-Photon | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Cell Membrane Permeability | Male | Cyclophosphamide - adverse effects | Cyclophosphamide - therapeutic use | Rituximab - therapeutic use | Blood-Brain Barrier - diagnostic imaging | Female | Recombinant Fusion Proteins - administration & dosage | Lymphoma, Non-Hodgkin - drug therapy | Rituximab - adverse effects | Neuroimaging - methods | Central Nervous System Neoplasms - metabolism | Prednisone - adverse effects | Treatment Outcome | Blood-Brain Barrier - drug effects | CD13 Antigens - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Lymphoma, Non-Hodgkin - metabolism | Recombinant Fusion Proteins - pharmacokinetics | Vincristine - therapeutic use | Biomarkers | Tumor Necrosis Factor-alpha - administration & dosage | Vincristine - adverse effects | Lymphoma, Non-Hodgkin - mortality | Tumor Necrosis Factor-alpha - pharmacokinetics | Central Nervous System Neoplasms - diagnosis | Central Nervous System Neoplasms - drug therapy | Research Design | Central Nervous System Neoplasms - mortality | Doxorubicin - adverse effects | Prednisone - therapeutic use | Lymphoma, Non-Hodgkin - diagnosis | Index Medicus | Abridged Index Medicus
Journal Article
Journal of the Peripheral Nervous System, ISSN 1085-9489, 09/2016, Volume 21, Issue 3, pp. 154 - 156
Journal Article
European Journal of Cancer, ISSN 0959-8049, 04/2018, Volume 93, pp. 57 - 68
Journal Article
by Fox, K.M and Bertrand, M and Ferrari, R and Remme, W.J and Simoons, M.L and Simoons, M and Bassand, J.P and Aldershvile, J and Hildebrandt, P and Cokkinos, D and Toutouzas, P and Eha, J and Erhardt, L and Erikssen, J and Grybauskas, P and Kalnins, U and Karsch, K and Sechtem, U and Keltai, M and Klein, W and Lüscher, T and Mulcahy, D and Nieminen, M and Oto, A and Ozsaruhan, O and Paulus, W and Providencia, L and Riecansky, I and Ruzyllo, W and Santini, U and Tavazzi, L and Soler-Soler, J and Widimsky, P and Julian, D and Dargie, H and Murray, G and Kübler, W and Thygesen, K and Duprez, D and Steg, G and Drexel, H and Gombotz, G and Duprez, D and Heyndrickx, G.H and Legrand, V and Materne, P and Van Mieghem, W and Bocek, P and Branny, M and Cech, M and Charouzek, J and Drazka, J and Fabik, L and Florian, J and Francek, L and Groch, L and Havranek, P and Hradec, J and Jansky, P and Jirmar, R and Jokl, I and Krejcova, H and Kvasnak, M and Maratka, T and Marcinek, G and Moravcova, J and Nedbal, P and Peterka, K and Povolny, J and Rosolova, H and Semrad, B and Sochor, K and Spacek, R and Spinar, J and Stipal, R and Stuchlik, K and Sulda, M and Ulman, J and Vaclavicek, A and Vojtisek, P and Bjerregaard-Andersen, H and Hildebrandt, P and Kristensen, K and Madsen, J.K and Markenvard, J and Meibom, J and Norgaard, A and Scheibel, M and Eha, J and Leht, A and Teesalu, R and Vahula, V and Itkonen, A and Juvonen, J and Karmakoski, J and Kilkki, E and Koskela, E and Melin, J and Nieminen, M.S and Savola, R and ... and EURopean Trial Reduction Cardiac E and EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators
The Lancet, ISSN 0140-6736, 09/2003, Volume 362, Issue 9386, pp. 782 - 788
Treatment with angiotensin-converting-enzyme (ACE) inhibitors reduces the rate of cardiovascular events among patients with left-ventricular dysfunction and... 
SURVIVAL | MEDICINE, GENERAL & INTERNAL | ACE | LEFT-VENTRICULAR DYSFUNCTION | MYOCARDIAL-INFARCTION | HYPERTENSION | EXPRESSION | CONVERTING-ENZYME-INHIBITORS | BLOOD-PRESSURE | CAPTOPRIL | Double-Blind Method | Follow-Up Studies | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Treatment Outcome | Cause of Death | Coronary Disease - mortality | Heart Failure - prevention & control | Angiotensin-Converting Enzyme Inhibitors - therapeutic use | Heart Arrest - prevention & control | Cardiovascular Diseases - mortality | Coronary Disease - drug therapy | Female | Myocardial Infarction - prevention & control | Perindopril - therapeutic use | Evaluation | Drug therapy | ACE inhibitors | Coronary heart disease | Cardiovascular agents | Cardiovascular disease | Heart attacks | Medical treatment | Morbidity | Clinical outcomes | Myocardial infarction | Risk | Subgroups | Reduction | Motivation | Peptidyl-dipeptidase A | Gangrene | Cardiology | Heart diseases | Heart failure | Hypertension | Stroke | Risk groups | Mortality | Coronary artery | Health risks | Risk reduction | Angina pectoris | Coronary artery disease | Disease control | Patients | Heart rate | Inhibitors | Coronary vessels | Angiotensin | Infarction | Diabetes | Ventricle | Cardiovascular diseases | Health risk assessment | Potassium
Journal Article